Please login to the form below

Not currently logged in
Email:
Password:

FDA panel wants study on AZ cancer drug

The US FDA Oncologic Drugs Advisory Committee has voted that AstraZeneca should complete a post-approval clinical trial for its investigational thyroid cancer drug, vandetanib

The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee voted on Thursday that AstraZeneca (AZ) should complete a post-approval clinical trial for the company's investigational drug vandetanib, which is a potential treatment for thyroid cancer.

The 10 panel members voted unanimously that the drug, which is intended for the treatment of unresectable locally advanced or metastatic medullary thyroid cancer, should be studied in an additional trial if it is approved in order to determine whether a lower dose could potentially be effective. The lower dose might help avoid some of the serious safety issues that have been observed in clinical trials, including a possible increase in the risk of stroke, the panelists said. 

The FDA did not ask the panel members to vote on whether or not the drug should be approved, but it did ask them to discuss the product's risk-benefit profile. In that discussion, the committee members generally acknowledged that the risk-benefit profile of vandetanib is acceptable in at least some patients. 

The once-daily, oral drug was granted a priority review by the FDA, as there is currently no approved treatment in the US for advanced medullary thyroid cancer. AstraZeneca expects a decision on the US marketing application by January 7, 2011. 

Vandetanib is also under review by the European Medicines Agency (EMA). 

3rd December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics